Drug Resistance Against Cancer Treatment

Dear Colleagues,

In the era when chemotherapy was the only option for “drug” therapy in cancer treatment, multidrug resistance (MDR) was a major hurdle that could suddenly render even the most effective treatments obsolete. In fact, MDR seemed to be so inevitable that it was known as a matter of “when”, rather than a matter of “if”. Chemotherapy is still at the forefront of cancer treatment, even following the introduction of molecularly targeted small molecule drugs, and therefore, the battle with MDR continues. While mechanisms involved in MDR might not apply to molecularly targeted drugs, the resistance to these drugs is also an ever-present threat. However, just like the drug itself, the resistance mechanisms (inherent or acquired) are more specific, often relating to the same signaling pathway that is the target of the drug.

This Special Issue aims to include research and review papers that provide the most recent information and developments on the ongoing battle with resistance against cancer treatment. The scope of the issue is to cover both MDR and resistance against molecularly targeted drugs. Our hope is to bring together a collective wisdom regarding our approach to drug resistance in cancer.

Dr. Hamidreza Montazeri Aliabadi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• multidrug resistance (MDR)
• chemotherapy
• P-glycoprotein (P-gp)
• ATP-binding cassette (ABC) transporters
• molecularly targeted drugs
• inherent resistance
• acquired resistance
• signaling pathways